
Visiomed Group SA (ALVMG) | Financial Analysis & Statements
Visiomed Group SA | Small-cap | Healthcare
Visiomed Group SA | Small-cap | Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
36.6M
Total Liabilities
11.8M
Shareholders Equity
24.7M
Debt to Equity
0.48
Cash Flow Metrics
Revenue & Profitability Trend
Visiomed Group SA Income Statement From 2020 to 2023
Metric | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|
Revenue | 13.7M | 14.4M | 7.2M | 19.0M |
Cost of Goods Sold | 7.4M | 11.2M | 7.9M | 22.7M |
Gross Profit | 6.3M | 3.2M | -715.0K | -3.8M |
Gross Margin % | 46.0% | 22.2% | -10.0% | -19.8% |
Operating Expenses | ||||
Research & Development | - | - | - | - |
Selling, General & Administrative | - | - | - | - |
Other Operating Expenses | 23.0K | 801.0K | 832.0K | -786.0K |
Total Operating Expenses | 23.0K | 801.0K | 832.0K | -786.0K |
Operating Income | 952.0K | -3.9M | -3.7M | -6.6M |
Operating Margin % | 6.9% | -27.1% | -51.3% | -34.8% |
Non-Operating Items | ||||
Interest Income | 112.0K | 4.0K | 12.0K | - |
Interest Expense | 1.2M | 182.0K | 618.0K | 382.0K |
Other Non-Operating Income | - | - | - | - |
Pre-tax Income | 1.5M | -5.1M | -4.2M | -5.2M |
Income Tax | -37.0K | 113.0K | 142.0K | -164.0K |
Effective Tax Rate % | -2.4% | 0.0% | 0.0% | 0.0% |
Net Income | 902.0K | -5.3M | -4.5M | -5.2M |
Net Margin % | 6.6% | -36.5% | -62.1% | -27.1% |
Key Metrics | ||||
EBITDA | 4.2M | -1.2M | -2.9M | -6.7M |
EPS (Basic) | €0.00 | €-0.02 | €-0.03 | €-0.20 |
EPS (Diluted) | €0.00 | €-0.02 | €-0.03 | €-0.20 |
Basic Shares Outstanding | 294356419 | 263850000 | 138087389 | 25382874 |
Diluted Shares Outstanding | 294356419 | 263850000 | 138087389 | 25382874 |
Income Statement Trend
Visiomed Group SA Balance Sheet From 2019 to 2023
Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 3.0M | 2.4M | 6.6M | 779.0K | - |
Short-term Investments | - | - | 7.0K | 31.0K | 415.0K |
Accounts Receivable | 1.2M | 1.8M | 4.6M | 252.0K | - |
Inventory | 0 | 658.0K | 1.4M | 1.3M | - |
Other Current Assets | - | 410.0K | 203.0K | 330.0K | -1.0K |
Total Current Assets | 5.3M | 7.0M | 16.0M | 5.1M | - |
Non-Current Assets | |||||
Property, Plant & Equipment | 7.3M | 13.0M | 8.5M | 1.0M | - |
Goodwill | 49.5M | 38.3M | 44.1M | 541.0K | - |
Intangible Assets | 356.0K | 374.0K | 90.0K | 97.0K | - |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 1.0K | -1.0K | -101.0K | 1.0K | - |
Total Non-Current Assets | 31.3M | 29.1M | 28.1M | 832.0K | - |
Total Assets | 36.6M | 36.1M | 44.1M | 5.9M | - |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 2.1M | 3.0M | 17.3M | 5.2M | - |
Short-term Debt | 287.0K | 127.0K | 0 | 2.0K | - |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | 310.0K | 13.0M | 69.0K | 38.0K |
Total Current Liabilities | 3.4M | 5.5M | 19.3M | 8.8M | - |
Non-Current Liabilities | |||||
Long-term Debt | 7.6M | 5.5M | 5.0M | 13.0K | - |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | -1.0K | -1.0K | 1.2M | 406.0K | - |
Total Non-Current Liabilities | 8.5M | 6.3M | 10.7M | 1.5M | - |
Total Liabilities | 11.8M | 11.8M | 30.0M | 10.3M | - |
Equity | |||||
Common Stock | 2.9M | 2.9M | 1.4M | 20.3M | - |
Retained Earnings | 902.0K | -5.3M | -4.5M | -36.7M | - |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 24.7M | 24.3M | 14.1M | -4.4M | - |
Key Metrics | |||||
Total Debt | 7.9M | 5.6M | 5.0M | 15.0K | 0 |
Working Capital | 1.9M | 1.5M | -3.3M | -3.7M | 0 |
Balance Sheet Composition
Visiomed Group SA Cash Flow Statement From 2020 to 2023
Metric | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|
Operating Activities | ||||
Net Income | 902.0K | -5.3M | -4.5M | -5.2M |
Depreciation & Amortization | - | - | - | - |
Stock-Based Compensation | - | - | - | - |
Working Capital Changes | 0 | 0 | 0 | 0 |
Operating Cash Flow | -1.3M | -5.3M | -4.5M | -5.2M |
Investing Activities | ||||
Capital Expenditures | -1.8M | -5.5M | -171.0K | 3.1M |
Acquisitions | - | - | - | - |
Investment Purchases | - | - | - | - |
Investment Sales | - | - | - | - |
Investing Cash Flow | -1.6M | -17.5M | -15.0M | 3.1M |
Financing Activities | ||||
Share Repurchases | - | - | - | - |
Dividends Paid | - | - | - | - |
Debt Issuance | 2.4M | 12.2M | 26.0M | 1.6M |
Debt Repayment | -1.3M | -650.0K | -713.0K | -1.6M |
Financing Cash Flow | 1.0M | 14.8M | 27.2M | 0 |
Free Cash Flow | -1.5M | -7.3M | -6.7M | -11.1M |
Net Change in Cash | -1.8M | -8.0M | 7.7M | -2.1M |
Cash Flow Trend
Visiomed Group SA Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
57.80
Forward P/E
5.75
Price to Book
2.10
Price to Sales
3.88
PEG Ratio
5.75
Profitability Ratios
Profit Margin
6.58%
Operating Margin
6.76%
Return on Equity
3.68%
Return on Assets
0.68%
Financial Health
Current Ratio
0.49
Debt to Equity
32.03
Beta
-0.62
Per Share Data
EPS (TTM)
€0.00
Book Value per Share
€0.08
Revenue per Share
€0.05
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
alvmg | 53.2M | 57.80 | 2.10 | 3.68% | 6.58% | 32.03 |
EssilorLuxottica | 123.5B | 51.90 | 3.26 | 6.44% | 8.74% | 36.58 |
Sartorius Stedim | 17.3B | 76.84 | 4.40 | 5.69% | 7.78% | 73.51 |
Crossject S.A | 85.4M | - | - | 478.68% | 0.00% | -7.88 |
Bonyf N.V | 7.8M | - | 17.50 | -1.38% | 8.02% | 0.00 |
Spineway S.A | 4.5M | 0.02 | 0.18 | -8.42% | -16.10% | 6.46 |
Financial data is updated regularly. All figures are in the company's reporting currency.